CDK4 and breast carcinoma: From a therapeutic standpoint, recent FDA approval of the CDK4/6 inhibitor palbociclib for the treatment of ER+/HER− breast cancer [24] emphasizes current interest in the CDK4/CDK6-cyclin D to RB1 signaling axis [25].